1. Home
  2. SLN vs UTL Comparison

SLN vs UTL Comparison

Compare SLN & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • UTL
  • Stock Information
  • Founded
  • SLN 1994
  • UTL 1984
  • Country
  • SLN United Kingdom
  • UTL United States
  • Employees
  • SLN N/A
  • UTL N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • UTL Power Generation
  • Sector
  • SLN Health Care
  • UTL Utilities
  • Exchange
  • SLN Nasdaq
  • UTL Nasdaq
  • Market Cap
  • SLN 919.6M
  • UTL 939.3M
  • IPO Year
  • SLN N/A
  • UTL N/A
  • Fundamental
  • Price
  • SLN $18.50
  • UTL $59.89
  • Analyst Decision
  • SLN Strong Buy
  • UTL
  • Analyst Count
  • SLN 4
  • UTL 0
  • Target Price
  • SLN $61.50
  • UTL N/A
  • AVG Volume (30 Days)
  • SLN 179.3K
  • UTL 62.1K
  • Earning Date
  • SLN 11-12-2024
  • UTL 11-05-2024
  • Dividend Yield
  • SLN N/A
  • UTL 2.81%
  • EPS Growth
  • SLN N/A
  • UTL 11.06
  • EPS
  • SLN N/A
  • UTL 3.01
  • Revenue
  • SLN $22,623,125.00
  • UTL $507,900,000.00
  • Revenue This Year
  • SLN N/A
  • UTL $0.88
  • Revenue Next Year
  • SLN $104.98
  • UTL $6.64
  • P/E Ratio
  • SLN N/A
  • UTL $20.16
  • Revenue Growth
  • SLN N/A
  • UTL N/A
  • 52 Week Low
  • SLN $6.51
  • UTL $44.71
  • 52 Week High
  • SLN $27.72
  • UTL $63.52
  • Technical
  • Relative Strength Index (RSI)
  • SLN 48.92
  • UTL 53.53
  • Support Level
  • SLN $18.20
  • UTL $57.02
  • Resistance Level
  • SLN $19.36
  • UTL $60.86
  • Average True Range (ATR)
  • SLN 0.88
  • UTL 1.14
  • MACD
  • SLN -0.04
  • UTL 0.10
  • Stochastic Oscillator
  • SLN 35.50
  • UTL 75.32

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About UTL UNITIL Corporation

Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. It reports three segments namely utility gas operations, utility electric operations, and non-regulated.

Share on Social Networks: